Open AccessEffects of dipeptidyl peptidase-4 inhibition on portal hypertensive and cirrhotic rats
Author(s) -
HuiChun Huang,
Shih-Kuang Hsu,
ChiaoLin Chuang,
Shao-Yu Hsiung,
ChiaMing Chang,
MingChih Hou,
Fa-Yauh Lee
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000636
Subject(s) - medicine , dipeptidyl peptidase 4 , saxagliptin , dipeptidyl peptidase , pharmacology , dipeptidyl peptidase 4 inhibitor , gastroenterology , endocrinology , sitagliptin , enzyme , biochemistry , diabetes mellitus , type 2 diabetes , chemistry , metformin , insulin
Portal hypertension is a pathophysiological abnormality with distinct vascular derangements associated with liver cirrhosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors are antidiabetic agents which exert pleiotropic vascular effects, but their relevant impact on portal hypertension and liver cirrhosis remains unclear. This study aims to clarify this issue.